Relationship of paraoxonase-1, malondialdehyde and mean platelet volume with markers of atherosclerosis in familial Mediterranean fever: An observational study;Ailevi Akdeniz ateşinde paraoksonaz-1, malondialdehit ve ortalama trombosit hacmi ile ateroskleroz belirteçlerinin ilişkisi: Gözlemsel bir çalışma

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 4, 2013, Pages 357-362

  Aritürk, Özlem Karakurt ^a   Üreten, Kemal ^b   Sari, Münevver ^c   Yazihan, Nuray ^d   Ermiş, Ezgi ^d   Ergüder, Imge ^d  

^a Balikesir State Hospital   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c Birecik State Hospital   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Familial Mediterranean fever; Malondialdehyde; Mean platelet volume; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; MALONALDEHYDE; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; SEDIMENTATION RATE; SYNDROME DELINEATION; THROMBOCYTE VOLUME; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; CYTOLOGY; THROMBOCYTE; THROMBOCYTE COUNT;

ADULT; ARYLDIALKYLPHOSPHATASE; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHOLESTEROL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; PLATELET COUNT; TRIGLYCERIDES;

EID: 84879268912     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.103     Document Type: Article

References (44)

1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of literature. Am J Med 1967; 43: 227-53. [CrossRef]
2. Daniels M, Shohat T, Brenner-Ullman A, Shohat M. Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish populations in Israel. Am J Med Genet 1995; 55: 311-4. [CrossRef]
3. Özen S, Karaaslan Y, Özdemir O, Saatçi U, Bakkaloǧlu A, Köroǧlu E, et al. Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol 1998; 25: 2445-9.
4. Lachmann HJ, Şengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology 2006; 45: 746-50. [CrossRef]
5. Tunca M, Ki{dotless}rkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet 1999; 353: 1415. [CrossRef]
6. Cali{dotless}şkan M, Güllü H, Yi{dotless}lmaz S, Erdoǧan D, Ünler GK, Çiftçi Ö, et al. Impaired coronary microvascular function in familial Mediterranean fever. Atherosclerosis 2007; 195: e161-7. [CrossRef]
7. Tavil Y, Üreten K, Öztürk MA, Şen N, Kaya MG, Cemri M, et al. The detailed assessment of left and right ventricular functions by tissue Doppler imaging in patients with familial Mediterranean fever. Clin Rheumatol 2008; 27:189-94. [CrossRef]
8. Ardi{dotless}ç I, Kaya MG, Yarlioǧlueş M, Doǧdu O, Çelikbilek M, Akpek M, et al. Assessment of heart rate recovery index in patients with familial Mediterranean fever. Rheumatol Int 2011; 31: 121-5. [CrossRef]
9. Akdoǧan A, Calguneri M, Yavuz B, Arslan EB, Kalyoncu U, Şahiner L, et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006; 48: 2351-3. [CrossRef]
10. Bilginer Y, Özalti{dotless}n F, Başaran C, Düzova A, Beşbaş N, Topaloǧlu R, et al. Evaluation of intima media thickness of the common and internal carotid arteries with inflammatory markers in familial Mediterranean fever as possible predictors for atherosclerosis. Rheumatol Int 2008; 28: 1211-6. [CrossRef]
11. Uǧurlu S, Seyahi E, Cetinkaya F, Özbaki{dotless}r F, Balci{dotless} H, Özdoǧan H. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology 2009; 48: 911-5. [CrossRef]
12. Terekeci HM, Öktenli C, Özgürtaş T, Nalbant S, Top C, Çelik S, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol 2008; 35: 2024-9.
13. Yüksel S, Ayvazyan L, Gasparyan AY. Familial Mediterranean fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J 2010; 23; 4:51-6. [CrossRef]
14. Akçay A, Acar G, Sayarli{dotless}oǧlu M, Sökmen A, Kaya H, Ispiroǧlu M, et al. QT dispersion and transmural dispersion of repolarization in patients with familial Mediterranean fever. Mod Rheumatol 2009; 19: 550-5. [CrossRef]
15. Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004; 50: 2309-15. [CrossRef]
16. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-72. [CrossRef]
17. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4. [CrossRef]
18. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler Thromb Vasc Biol 1998; 18: 1617-24. [CrossRef]
19. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice, Circulation 2002; 106: 484-90. [CrossRef]
20. Yi{dotless}ldi{dotless}z A, Gür M, Yi{dotless}lmaz R, Demirbaǧ R, Polat M, Selek S, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008: 197; 257-63. [CrossRef]
21. Gür M, Yi{dotless}ldi{dotless}z A, Demirbaǧ R, Yi{dotless}lmaz R, Aslan M, Özdoǧru I, et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coron Artery Dis 2007; 18: 89-95. [CrossRef]
22. Azarsi{dotless}z E, Kayi{dotless}kçi{dotless}oǧlu M, Payzi{dotless}n S, Yi{dotless}ldi{dotless}ri{dotless}m Sözmen E. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 2003: 91; 43-51. [CrossRef]
23. Gür M, Aslan M, Yi{dotless}ldi{dotless}z A, Demirbaǧ R, Yi{dotless}lmaz R, Selek S, et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006: 36; 779-87. [CrossRef]
24. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19; 330-5. [CrossRef]
25. Feingold KR, Memon RA, Moser AH, Grunfld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307-15. [CrossRef]
26. Harangi M, Seres I, Magyar MT, Csipo I, Sipka S, Valikovics A, et al. Association between human paraoxonase 1 activity and intimamedia thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc Dis 2008; 25: 122-8. [CrossRef]
27. Tartan Z, Orhan G, Kaşi{dotless}kçi{dotless}oǧlu H, Uyarel H, Ünal S, Özer N, et al. The role of paraoxonase (PON) enzyme in the extent and severity of the coronary artery disease in type-2 diabetic patients. Heart Vessels 2007; 22: 158-64. [CrossRef]
28. Granér M, James RW, Kahri J, Nieminen MS, Syvanne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006; 47: 2429-35. [CrossRef]
29. Lucchi L, Iannone A, Bergamini S, Stipo L, Perrone S, Uggeri S, et al. Comparison between hydroperoxides and malondialdehyde as markers of acute oxidative injury during hemodialysis. Artif Organs 2005; 29: 832-7. [CrossRef]
30. Schultheiss HP, Tschoepe D, Esser J, Schwippert B, Roesen P, Nieuwenhuis HK. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994; 24: 243-7. [CrossRef]
31. O'Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke 1995; 26: 995-9. [CrossRef]
32. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
33. Dahle LK, Hill EG, Holman RT. The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 1962; 98: 253-61. [CrossRef]
34. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-94. [CrossRef]
35. Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 83-91. [CrossRef]
36. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003; 72: 2877-85. [CrossRef]
37. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci 2003; 73: 2807-15. [CrossRef]
38. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, et al. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 2006; 26: 1806-13. [CrossRef]
39. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, et al. Anti-inflammatory therapy with tumor necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 868-72. [CrossRef]
40. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a populationbased study. Arthritis Rheum 2005; 52: 722-32. [CrossRef]
41. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15. [CrossRef]
42. Karaguezyan KG, Haroutjunian VM, Mamiconyan RS, Hakobian GS, Nazaretian EE, Hovsepyan LM, et al. Evidence of oxidative stress in erythrocyte phospholipid composition in the pathogenesis of familial Mediterranean fever (periodical disease). J Clin Pathol 1996; 49: 453-5. [CrossRef]
43. Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001; 3: 9-12.
44. Rao AK, Goldberg RE, Walsh PN. Platelet coagulant activities in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J Lab Clin Med 1984; 103: 82-92.